Literature DB >> 26178987

Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.

Victoria E K Walker-Sperling1, Valerie J Cohen1, Patrick M Tarwater2, Joel N Blankson3.   

Abstract

UNLABELLED: The "shock and kill" model of human immunodeficiency virus type 1 (HIV-1) eradication involves the induction of transcription of HIV-1 genes in latently infected CD4(+) T cells, followed by the elimination of these infected CD4(+) T cells by CD8(+) T cells or other effector cells. CD8(+) T cells may also be needed to control the spread of new infection if residual infected cells are present at the time combination antiretroviral therapy (cART) is discontinued. In order to determine the time frame needed for CD8(+) T cells to effectively prevent the spread of HIV-1 infection, we examined the kinetics of HIV transcription and virus release in latently infected cells reactivated ex vivo. Isolated resting, primary CD4(+) T cells from HIV-positive (HIV+) subjects on suppressive regimens were found to upregulate cell-associated HIV-1 mRNA within 1 h of stimulation and produce extracellular virus as early as 6 h poststimulation. In spite of the rapid kinetics of virus production, we show that CD8(+) T cells from 2 out of 4 viremic controllers were capable of effectively eliminating reactivated autologous CD4(+) cells that upregulate cell-associated HIV-1 mRNA. The results have implications for devising strategies to prevent rebound viremia due to reactivation of rare latently infected cells that persist after potentially curative therapy. IMPORTANCE: A prominent HIV-1 cure strategy termed "shock and kill" involves the induction of HIV-1 transcription in latently infected CD4(+) T cells with the goal of elimination of these cells by either the cytotoxic T lymphocyte response or other immune cell subsets. However, the cytotoxic T cell response may also be required after curative treatment if residual latently infected cells remain. The kinetics of HIV-1 reactivation indicate rapid upregulation of cell-associated HIV-1 mRNA and a 5-h window between transcription and virus release. Thus, HIV-specific CD8(+) T cell responses likely have a very short time frame to eliminate residual latently infected CD4(+) T cells that become reactivated after discontinuation of antiretroviral therapy following potentially curative treatment strategies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26178987      PMCID: PMC4542348          DOI: 10.1128/JVI.01454-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity.

Authors:  Leor S Weinberger; John C Burnett; Jared E Toettcher; Adam P Arkin; David V Schaffer
Journal:  Cell       Date:  2005-07-29       Impact factor: 41.582

2.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.

Authors:  Y Zhu; T Pe'ery; J Peng; Y Ramanathan; N Marshall; T Marshall; B Amendt; M B Mathews; D H Price
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

3.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors:  T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  Viral dynamics of acute HIV-1 infection.

Authors:  S J Little; A R McLean; C A Spina; D D Richman; D V Havlir
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

6.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

8.  Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.

Authors:  S Kinoshita; B K Chen; H Kaneshima; G P Nolan
Journal:  Cell       Date:  1998-11-25       Impact factor: 41.582

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.

Authors:  O Schwartz; V Maréchal; S Le Gall; F Lemonnier; J M Heard
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  8 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.

Authors:  Gemma Hancock; Sara Morón-López; Jakub Kopycinski; Maria C Puertas; Eleni Giannoulatou; Annie Rose; Maria Salgado; Emma-Jo Hayton; Alison Crook; Catharine Morgan; Brian Angus; Fabian Chen; Hongbing Yang; Javier Martinez-Picado; Tomas Hanke; Lucy Dorrell
Journal:  J Int AIDS Soc       Date:  2017-05-19       Impact factor: 5.396

3.  Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.

Authors:  Julia A Sung; Katherine Sholtis; Jennifer Kirchherr; Joann D Kuruc; Cynthia L Gay; Jeffrey L Nordstrom; Catherine M Bollard; Nancie M Archin; David M Margolis
Journal:  EBioMedicine       Date:  2017-07-29       Impact factor: 8.143

4.  Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection.

Authors:  Jimena Salido; María Julia Ruiz; César Trifone; María Inés Figueroa; María Paula Caruso; María Magdalena Gherardi; Omar Sued; Horacio Salomón; Natalia Laufer; Yanina Ghiglione; Gabriela Turk
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

5.  Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV.

Authors:  Marta Calvet-Mirabent; Ildefonso Sánchez-Cerrillo; Noa Martín-Cófreces; Pedro Martínez-Fleta; Hortensia de la Fuente; Ilya Tsukalov; Cristina Delgado-Arévalo; María José Calzada; Ignacio de Los Santos; Jesús Sanz; Lucio García-Fraile; Francisco Sánchez-Madrid; Arantzazu Alfranca; María Ángeles Muñoz-Fernández; Maria J Buzón; Enrique Martín-Gayo
Journal:  EBioMedicine       Date:  2022-06-02       Impact factor: 11.205

Review 6.  Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel preventive and cure strategies against HIV-1?

Authors:  Marta Calvet-Mirabent; Enrique Martín-Gayo
Journal:  Curr Opin HIV AIDS       Date:  2022-07-25       Impact factor: 4.061

7.  The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Patrick M Tarwater; Joel N Blankson
Journal:  EBioMedicine       Date:  2016-04-18       Impact factor: 8.143

8.  Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.

Authors:  Julie Boucau; Jishnu Das; Neelambari Joshi; Sylvie Le Gall
Journal:  PLoS Pathog       Date:  2020-03-20       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.